Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has been given an average rating of “Buy” by the eleven analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $22.00.
Several equities analysts have issued reports on the company. Mizuho reissued a “buy” rating and issued a $28.00 price target on shares of Aerie Pharmaceuticals in a research note on Monday, December 28th. HC Wainwright restated a “buy” rating on shares of Aerie Pharmaceuticals in a report on Monday, March 1st. Finally, Needham & Company LLC started coverage on shares of Aerie Pharmaceuticals in a report on Friday, February 5th. They issued a “buy” rating and a $26.00 target price on the stock.
Shares of AERI stock opened at $18.04 on Monday. The company has a debt-to-equity ratio of 3.41, a quick ratio of 3.10 and a current ratio of 3.33. Aerie Pharmaceuticals has a fifty-two week low of $9.01 and a fifty-two week high of $21.30. The company has a market cap of $846.38 million, a PE ratio of -4.31 and a beta of 0.79. The stock’s fifty day moving average price is $18.40 and its two-hundred day moving average price is $14.51.
Institutional investors have recently added to or reduced their stakes in the stock. Schroder Investment Management Group lifted its position in shares of Aerie Pharmaceuticals by 22.5% during the fourth quarter. Schroder Investment Management Group now owns 1,402,975 shares of the company’s stock worth $18,954,000 after acquiring an additional 257,300 shares in the last quarter. Norges Bank purchased a new position in Aerie Pharmaceuticals during the 4th quarter valued at about $3,310,000. Pinnacle Associates Ltd. increased its position in shares of Aerie Pharmaceuticals by 42.4% during the fourth quarter. Pinnacle Associates Ltd. now owns 746,197 shares of the company’s stock valued at $10,081,000 after buying an additional 222,137 shares during the period. Voloridge Investment Management LLC lifted its holdings in shares of Aerie Pharmaceuticals by 103.4% in the third quarter. Voloridge Investment Management LLC now owns 205,170 shares of the company’s stock worth $2,415,000 after buying an additional 104,282 shares in the last quarter. Finally, DNB Asset Management AS bought a new position in shares of Aerie Pharmaceuticals in the fourth quarter valued at approximately $1,408,000. Institutional investors and hedge funds own 99.89% of the company’s stock.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma.
Recommended Story: Dual Listing What You Need to Know
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.